A new Rutgers University study published in the journal Health Affairs shows use of a long-acting injectable form of opioid treatment has increased nationwide and in New Jersey, but lags other versions of the medication.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
